Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06134843
Other study ID # VMD2022-002
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 1, 2024
Est. completion date April 15, 2025

Study information

Verified date June 2024
Source Vitruvian Medical Devices, Inc.
Contact David M Young, MD
Phone (415) 347-5332
Email dyoungucsfplastics@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study to determine whether the combination biologic/drug DERMASEAL will safely decrease donor wound pain after split-thickness skin graft surgery. Participants will have their skin graft donor sites immediately treated with DERMASEAL versus standard of care wound dressings followed by periodic monitoring of their recovery.


Description:

This is a single center, single-blind, randomized, controlled phase 1/2 study of patients undergoing treatment of a cutaneous wound involving a split-thickness skin graft. A subject's study duration will be for up to a total of 16 weeks from randomization to end of study. This includes 1 week of treatment, followed by 3 weeks of Standard of Care plus a final follow-up visit 12 weeks after complete wound closure or the end of Standard of Care.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 12
Est. completion date April 15, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: 1. Men or women = 21 years of age. 2. The subject is able and willing to adhere to study procedures and informed consent is obtained. 3. Patient scheduled to undergo a split-thickness skin graft > 25 cm2 and = 300 cm2 with a wound depth of between 0.010 - 0.015 inch (0.2 - 0.4 mm). 4. Target donor site wound involving the torso or upper or lower extremities. 5. Patient has a palpable pulse at the wrist or ankle indicating adequate arterial perfusion of the extremity from which the skin graft is harvested. 6. Serum creatinine <2.0 mg/dl within the last 6 months. 7. Negative urine pregnancy test at screening for women of childbearing potential. i) Women participants are considered of non-childbearing potential if they are pre-menopausal with a documented hysterectomy or bilateral oophorectomy; or post-menopausal defined as the cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; or have a serum FSH level confirming the post-menopausal state. Exclusion Criteria: 1. Hypersensitivity to silver or fresh frozen plasma. 2. Active infection or history of radiation to the donor site. 3. Insensate at the donor site. 4. Elevated INR>3.0. 5. The subject was previously entered into this study or had participated in any study drug or medical device study within 30 days of screening. 6. Currently on a treatment regimen or medications which in the opinion of the investigator are known to interfere with wound healing (for example: cancer chemotherapy or equivalent immunosuppressants, systemic steroids > 10 days of treatment, cytostatic drugs, COX-2 inhibitors, or radiation therapy). 7. Excessive lymphedema that in the opinion of the investigator will interfere with wound healing. 8. A cognitive, physical, or psychological condition interfering with subject's ability to comply with the treatment regimen. 9. Subject is on dialysis. 10. Patients who are pregnant, breast feeding, or unwilling to practice contraceptive methods during participation in the study, if applicable. Effective methods of contraception include: i. oral, injectable, or implanted hormonal contraceptives ii. intrauterine device or system, iii. barrier method with spermicide, or iv. bilateral tubal occlusion. 11. Patients with uncontrolled anemia (Hgb<10 g/dL in women; <12 g/dL in men) at Screening. 12. Severe malnutrition (serum albumin =2.0 with a normal CRP).

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
DERMASEAL
plasma film containing metallic silver microparticles and fibrin

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Hobart W. Harris Vitruvian Medical Devices, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary adverse events The safety of topically applying a plasma film containing metallic silver microparticles plus fibrin in patients with skin graft donor sites for 16 weeks following split-thickness skin grafting. 16 weeks
Primary wound pain The study will evaluate if using DERMASEAL is associated with a clinically meaningful difference in pain score (=2 points on the Visual Analog Scale; minimal score =0 and maximal score = 10. A higher score means more pain) between the treatment and active control arms at any time during the 16-week study. 16 weeks
Secondary Percent wound healing Percent of donor site wounds healed during the post-treatment weeks 1 through 4 4 weeks
Secondary Time to complete wound closure Time to complete donor site wound closure during the post-treatment weeks 1 through 4 4 weeks
Secondary Recurrent donor site wound after complete wound closure Recurrence of donor site after complete wound closure, requiring treatment, at any time during the 16-week study. 16 weeks
Secondary Scarring Scarring as measured by the Vancouver Scar Scale at 16 weeks after surgery. The minimum value = 0 and maximal value = 13; higher scores mean a worse outcome. 16 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT02994589 - A Comparison of OASIS Wound Matrix With Approved Dressings for Skin Graft Donor Sites Phase 4
Terminated NCT03937765 - The Effect of Platelet Rich Plasma on Pain at Skin Graft Donor Sites N/A
Not yet recruiting NCT05367726 - The Contributions of the Multidisciplinary Management of Prosthesis Knee Infections in a Reference Center: A Retrospective Study About 52 Cases.Skin Coverage in a Reference Center: A Retrospective Study About 52 Cases
Not yet recruiting NCT06379724 - Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft Phase 4
Terminated NCT04014400 - Suprathel Versus Xeroform for the Management of Skin Graft Donor Sites N/A
Recruiting NCT04648267 - Factors Affecting Split Thickness Skin Graft Success Rates in Patients Who Underwent a Radial Forearm or Fibula Free Flap N/A
Withdrawn NCT03548610 - Efficacy and Safety of a Nanofat-seeded Biological Scaffold in Healing Lower Limb Surgical Defects N/A
Completed NCT04231305 - Antithrombotics and Complications in Skin Grafts
Recruiting NCT05447793 - Effectiveness and Tolerability of Fitostimoline Plus vs Connettivina Bio Plus in Skin Graft
Completed NCT06170424 - Retrospective Analysis of Spray Skin Treats for Severe Burns
Recruiting NCT04186273 - Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2. Phase 2